Central and eastern European nations still lag behind Western countries in science. But they are slowly catching up.
T wenty years after the end of Soviet communism, many of the former satellite states in central and eastern Europe have joined the West as members of the European Union (EU). Yet by many measures, the science being done in those states still lags behind. Not only do their overall public and private scientific expenditures tend to be lower than those of their EU partners, as are their levels of participation in EU-funded research collaborations, but their very academic structures also remain a barrier to international competitiveness. This is not to say that nothing has happened since 1989 -a year in which the fall of the Berlin Wall was paralleled by the near-collapse of academic and industrial science throughout the former Eastern bloc. The former German Democratic Republic, for example, has now caught up with the rest of western Europe owing to massive investment after the reunification of Germany in 1990. And the small Baltic country of Estonia, which spent that same period overhauling its Soviet-style academic structures and introducing a modern funding system based on grants, publications and peer review, has become a poster child for successful transition to Western-style science. Today it boasts considerable strengths in material, biomedical and environmental technologies.
But elsewhere, the academic hierarchy has often proved more resistant to change. Granted, countries including Hungary, Slovenia, the Czech Republic and Poland have seen the emergence of excellent research groups and institutes, many of them led by scientists who graduated around 1989 and were quick to grasp the opportunity to leave and gather experience abroad (see page 586). The International Institute of Molecular and Cell Biology in Warsaw, set up in 1999 with support from the United Nations Educational, Scientific and Cultural Organization (UNESCO), is a prominent example.
With the exception of Estonia, however, basic research in the region is still controlled by the national academies of science: governmentfunded organizations that independently operate numerous research institutes. Most of these academies have undergone evaluations of their respective strengths and weaknesses over the past decade, with the result that some of the least-productive institutes have been closed or restructured. And the knee-jerk opposition to the 'Westernization' of science is rapidly declining, as is political resentment and antiWestern ideology in general. Still, not all of these academy institutes are as well connected to the outside world of science as they should be. Young scientists there have good reason to complain about academic hierarchies whose existence is unjustified by scientific merit, and about funding channels that fail to reward the best research proposals.
Addressing their complaints will require the reinforcement of merit-based science in central and eastern Europe, which in turn will require that scarce resources are focused on existing and emerging strengths. The current economic crisis must not lead to a lasting decline in funding for science and higher education, either in Hungary, which has been hit particularly hard, or elsewhere in the region. The various national labs and institutions should reward mobility more than they have done in the past, as any upswing in their own scientific establishments will require that as many students and young scientists as possible gain experience in the best labs abroad. Finally, the region would gain substantial prestige and visibility if a large multinational research facility, such as the planned European Spallation Source, were to be built in one of the new EU member states.
Globally, science has benefited greatly from the flow of talent from eastern Europe and Russia over the past 20 years. That brain drain has not made the transition at home any easier. Although it has taken more time than anticipated to put central and eastern Europe back on the global map of science, the upcoming generation of young, energetic students and scientists should be able to complete the process. It would be to everybody's gain. The heart of Europe deserves good science, but the rest of the world needs good science from this culturally rich region just as much.
■

Containing risk
The US Department of Homeland Security should not be put in charge of biodefence research.
T he past few months have brought a rich harvest of high-level reports on US biosecurity, with a particular focus on the nearly 1,400 American labs known to be doing research on human, plant and animal pathogens risky enough to require special containment. The reports were largely inspired by the announcement from the US Federal Bureau of Investigation in August 2008 that Bruce Ivins, a senior researcher at the US Army Medical Research Institute of Infectious Diseases in Fort Detrick, Maryland, was considered to be the "sole culprit" in the deadly 2001 anthrax attacks. Several of the reports -two of them issued last week -recommend that a single agency be put in overall charge of what is now a fragmented oversight system involving at least a dozen agencies. Their laudable goal is to tighten the safeguards against biological threats, including any that might emanate from within the labs, without stifling research on countermeasures against any future attacks.
As always, however, the devil lies in the details. Opponents of the bill are also concerned by its designation of a new category of 'Tier I' agents for extra-tight regulation, including new levels of scrutiny to establish "personnel reliability". Lieberman said last week that only about eight microbes would fit this category. But the bill allows the secretary of homeland security to move any human pathogen into Tier I at any time, without having to provide a reason in public. This contrasts with the checks and balances -including consultation with scientists and public comment and discussionnow required to add a microorganism to the list of those overseen by the CDC or the agriculture department.
The fear is that the new Tier I requirements, and the costs they imply, would discourage labs from working on such pathogens. There is also the possibility that individual scientists will decide to choose microorganisms -or fields -more congenial to personal privacy. Already, researchers who work with any of the current 82 agents on the CDC's list must submit to a Department of Justice background check that involves fingerprinting and access to personal financial and medical records. At a recent American Society of Virology meeting in Vancouver, Canada, informal talk was about research being driven into Canada or the European Union, and the risk to careers associated with listed-agent work if labs begin to walk away from its costs.
Lieberman and Collins undoubtedly have good intentions with this bill. But they would be well advised to consult more carefully with front-line researchers before finalizing legislation in which so much is at stake. They should particularly consider the long experience and expertise resident in the CDC before making such a dramatic shift of lab oversight to an untried department.
■
Delimiting death
Procuring organs for transplant demands a realistic definition of life's end. P rompted by the increasing practice of organ transplantation, and thus the need to procure donor organs that are as fresh as possible, many countries have modelled their legal definition of death on a US law passed in 1981 after extensive debate and thoughtful input from a specially appointed president's commission of experts.
The law seems admirably straightforward: "An individual who has sustained either (1) irreversible cessation of circulatory and respiratory functions, or (2) irreversible cessation of all functions of the entire brain, including the brain stem, is dead. "
In practice, unfortunately, physicians know that when they declare that someone on life support is dead, they are usually obeying the spirit, but not the letter, of this law. And many are feeling increasingly uncomfortable about it.
In particular, they struggle with three of the law's phrases: 'irreversible' , 'all functions' and 'entire brain' , knowing that they cannot guarantee full compliance. They do know that when they declare a death -according to strict clinical criteria, the principles of which are outlined in the original report of the president's commission -that the person is to all intents and purposes dead. But what if, as is sometimes the case, blood chemistry suggests that the pituitary gland at the base of the brain is still functioning? That activity has nothing to do with a person being alive in any meaningful sense. But it undermines a claim that all functions of the entire brain have ceased. As do post-mortem observations that relatively large areas of tissue can be metabolically active in different brain areas at the time death is declared.
The criterion of irreversibility raises the question of how long one should wait to be sure that no function will re-emerge. Is the six hours recommended in the commission's report sufficient? Physicians who have been required by circumstance to wait much longer have occasionally observed a brainstem-mediated reflex -a cough, for example -up to 36 hours after they would have declared death. The problem is that death is not a phase transition whereby a person stops being alive and becomes dead in an instant. It is a long process during which systems, networks and cells gradually disintegrate. At some point, the person is no longer there, and can never be made to return. But the kind of clear, unambiguous boundary assumed in the 1981 law simply does not exist.
Ideally, the law should be changed to describe more accurately and honestly the way that death is determined in clinical practice. Most doctors have hesitated to say so too loudly, lest they be caricatured in public as greedy harvesters eager to strip living patients of their organs. But their public silence was broken on 24 September at an international meeting that included physicians, transplant surgeons and bioethicists at the Italian Festival of Health in Viareggio. The meeting concluded that lawmakers in the United States and elsewhere should reconsider rigid definitions of death, and called for a wider public debate.
The time has come for a serious discussion on redrafting laws that push doctors towards a form of deceit. But care must be taken to ensure that it doesn't backfire. Learning that the law has not been strictly adhered to could easily discourage organ donation at a time when demand for organs already vastly exceeds supply. Physicians and others involved in the issue would be wise to investigate just how incendiary the theme might be, perhaps in contained focus groups, and design their strategy accordingly.
Few things are as sensitive as death. But concerns about the legal details of declaring death in someone who will never again be the person he or she was should be weighed against the value of giving a full and healthy life to someone who will die without a transplant. ■
